J.B. Chemicals & Pharmaceuticals (JBCPL) has received its board’s approval for entering into a definitive agreement to sell its Russia/CIS OTC Business to Cilag GmbH International, a wholly owned subsidiary of Johnson & Johnson. The consideration for this transaction is Rs 9,385.10 million.
Further, the board has also approved the sale of worldwide rights and registrations of 3 OTC brands (Doktor Mom, Rinza and Fitovit) to Cilag, for an additional consideration of Rs 60.67 million. The Russia/CIS OTC Business is being sold as a going concern on a slump sale basis including OTC trademarks, brands, patents, registrations and domain names. The sale will also involve the transfer of the employees of the Russia/ CIS OTC Business.
Cilag‘s affiliate, Johnson & Johnson LLC, has also entered into a contract with the company’s wholly owned subsidiary situated in Russia for purchase of its OTC inventory and receivables for a consideration of $47 million. In addition, the company has signed a long term agreement to supply Cilag finished products for the acquired Russia/CIS OTC Business. The transaction is expected to close in mid 2011.
JBCPL is one of India’s leading pharmaceutical companies which manufacture and markets a diverse range of pharmaceutical formulations, herbal remedies and APIs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: